Skip to main content

Advertisement

Table 1 Progression for 2560 AREDS AMD (Category 1–3 at Baseline) patients over 10.3 years (Yu et al. [4])

From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

AMD category n Progressed to next stage No progression
1 713 494 (69 %) 219 (31 %)
2 1190 376 (32 %) 814 (68 %)
3 1527 578 (8 %) 949 (62 %)
3–4 280 280 (18 %) NA
3–5 298 298 (20 %) NA
  1. Includes patients treated and not treated with AREDS supplements [5]
  2. AREDS Age-Related Eye Disease Study, AMD age-related macular degeneration, NA not applicable